胰腺癌的恶性程度极高且预后极差,其病死率约占年发病人数的98%.以联合放化疗为主的综合治疗是局部晚期及转移性胰腺癌主要的治疗手段,但疗效有限.多项研究结果以及荟萃分析证实了吉西他滨在晚期胰腺癌中应用的优势,目前吉西他滨已成为晚期胰腺癌一线化疗的首选药物.虽然以吉西他滨为基础的联合方案被广泛应用于晚期胰腺癌的治疗,但仍缺乏足够的循证医学证据支持联合方案优于单药,所以最佳化疗的手段及方案仍需进一步研究证实.随着新的化疗药物以及靶向药物的出现,给晚期胰腺癌患者带来了新的希望.%With a high invasive ability and poor prognosis, the morbidity of pancreatic cancer is about 98%.Combination of chemotherapy and radiotherapy is the primary management for locoregionally advanced pancreatic cancer, but its efficacy is limited. Results from a number of meta-analysis have confirmed that gemcitabine is associated with significantly better clinical response and one-year overall survival rates;therefore, currently gemcitabine is the standard chemotherapy for advanced pancreatic cancer. Gemcitabine-based multi-drug regimens may have potentially favorable effects on patients' survival. However, evidence from phase Ⅲ clinical trials is lacking. Newer chemotherapy and targeted therapy agents are clearly needed for patients with advanced pancreatic cancer.
展开▼
